TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

AI Briefing

• – TG Therapeutics to present BRIUMVI data at American Academy of Neurology 2026 annual meeting
• – BRIUMVI shows real-world effectiveness, safety, and tolerability in patients with relapsing multiple sclerosis
• – TG Therapeutics to expand clinical and real-world data supporting BRIUMVI as an important treatment option for adults with relapsing multiple sclerosis